These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 9931308

  • 1. A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain.
    Lam LP, Chow RY, Berger SA.
    Biochem J; 1999 Feb 15; 338 ( Pt 1)(Pt 1):131-8. PubMed ID: 9931308
    [Abstract] [Full Text] [Related]

  • 2. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R, Bernstein A, Watring N, Linnekin D.
    Cancer Res; 2003 Aug 01; 63(15):4412-9. PubMed ID: 12907613
    [Abstract] [Full Text] [Related]

  • 3. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R.
    Biochem Biophys Res Commun; 2005 Nov 11; 337(1):1-13. PubMed ID: 16129412
    [Abstract] [Full Text] [Related]

  • 4. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line.
    Hashimoto K, Tsujimura T, Moriyama Y, Yamatodani A, Kimura M, Tohya K, Morimoto M, Kitayama H, Kanakura Y, Kitamura Y.
    Am J Pathol; 1996 Jan 11; 148(1):189-200. PubMed ID: 8546206
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
    Vempati S, Reindl C, Wolf U, Kern R, Petropoulos K, Naidu VM, Buske C, Hiddemann W, Kohl TM, Spiekermann K.
    Clin Cancer Res; 2008 Jul 15; 14(14):4437-45. PubMed ID: 18628457
    [Abstract] [Full Text] [Related]

  • 7. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
    Wai DH, Knezevich SR, Lucas T, Jansen B, Kay RJ, Sorensen PH.
    Oncogene; 2000 Feb 17; 19(7):906-15. PubMed ID: 10702799
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase.
    Tsujimura T, Kanakura Y, Kitamura Y.
    Leukemia; 1997 Apr 17; 11 Suppl 3():396-8. PubMed ID: 9209403
    [Abstract] [Full Text] [Related]

  • 11. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A, Zoltan-Jones A, Strizzi L, Bargo S, Kimura K, Salomon D, Callahan R.
    Oncogene; 2007 Feb 01; 26(5):662-72. PubMed ID: 16878155
    [Abstract] [Full Text] [Related]

  • 12. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
    Zermati Y, De Sepulveda P, Féger F, Létard S, Kersual J, Castéran N, Gorochov G, Dy M, Ribadeau Dumas A, Dorgham K, Parizot C, Bieche Y, Vidaud M, Lortholary O, Arock M, Hermine O, Dubreuil P.
    Oncogene; 2003 Feb 06; 22(5):660-4. PubMed ID: 12569358
    [Abstract] [Full Text] [Related]

  • 13. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S, Bergholz U, Jücker M, McCubrey JA, Trümper L, Stocking C, Bäsecke J.
    Oncogene; 2008 Jul 03; 27(29):4096-106. PubMed ID: 18317450
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.
    Kim SY, Kang JJ, Lee HH, Kang JJ, Kim B, Kim CG, Park TK, Kang H.
    Biochem Biophys Res Commun; 2011 Jul 01; 410(2):224-8. PubMed ID: 21640708
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Expression, purification, and characterization of Bacneu. A soluble protein tyrosine kinase domain encoded by the neu-oncogene.
    Myers JN, LeVea CM, Smith JE, Kallen RG, Tung L, Greene MI.
    Receptor; 1992 Jul 01; 2(1):1-16. PubMed ID: 1362129
    [Abstract] [Full Text] [Related]

  • 17. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene MI.
    Oncogene; 1989 Oct 01; 4(10):1175-83. PubMed ID: 2571965
    [Abstract] [Full Text] [Related]

  • 18. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation.
    Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y.
    Blood; 1994 May 01; 83(9):2619-26. PubMed ID: 7513208
    [Abstract] [Full Text] [Related]

  • 19. Modifications of tumor histology by point mutations in the v-fps oncogene: possible role of extracellular matrix.
    Auersperg N, Pawson T, Worth A, Weinmaster G.
    Cancer Res; 1987 Dec 01; 47(23):6341-8. PubMed ID: 3315185
    [Abstract] [Full Text] [Related]

  • 20. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.
    Piao X, Bernstein A.
    Blood; 1996 Apr 15; 87(8):3117-23. PubMed ID: 8605325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.